ABIVAX Société Anonyme

Healthcare · Biotechnology · France

Last price 86.59 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 7.69B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.